ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Cunsi Shen

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5113956095. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy. Co-author DOI 10.1007/s00210-024-03628-0 ↗
Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor rec… Last author DOI 10.1007/s10787-021-00848-1 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhengguang Zhang · 2 shared papers, 2021–2025 · strength 0.46
- Paper Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy. DOI 10.1007/s00210-024-03628-0 ↗
- Paper Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling… DOI 10.1007/s10787-021-00848-1 ↗
Fuqiong Zhou · 1 shared paper, 2025 · strength 0.30
- Paper Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy. DOI 10.1007/s00210-024-03628-0 ↗
Min Li · 1 shared paper, 2025 · strength 0.30
- Paper Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy. DOI 10.1007/s00210-024-03628-0 ↗
Meijuan Chen · 1 shared paper, 2021 · strength 0.16
- Paper Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling… DOI 10.1007/s10787-021-00848-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.